Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Oncology APIs. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN113801062B reveals a novel Grignard-based route for Entrectinib intermediates, offering significant cost reduction and safer manufacturing compared to traditional Suzuki coupling methods.
Patent CN108409648B details an energy-efficient synthesis of sorafenib intermediates with high purity, offering significant cost reduction in API manufacturing and scalable production capabilities.
Advanced preparation method for HER2 inhibitor Tucatinib using Pd(acac)2 catalysis. Offers high purity, simplified purification, and cost-effective manufacturing for pharma supply chains.
Patent CN107235910B reveals a high-purity synthesis route for Nilotinib intermediates, offering significant cost reduction and scalable manufacturing for global supply chains.
Discover the novel 6-step preparation method for CDK4/6 inhibitor SHR6390. Enhanced yield, mild conditions, and scalable process for high-purity pharmaceutical intermediates.
Patent CN102295638A details a novel one-pot method for Lapatinib synthesis, eliminating toxic tin reagents and improving purity for reliable API intermediate supply chains.
Patent CN113816955B reveals a high-purity route for RET kinase inhibitor intermediate. Discover cost-effective manufacturing and supply chain advantages.
Novel 5-step synthesis of Trilaciclib via CN114014864A. Offers high purity, mild conditions, and cost-effective manufacturing for global pharmaceutical supply chains.
Discover a novel Cytosine-based route for Palbociclib parent nucleus. Enhance purity to >99% and reduce costs in pharmaceutical manufacturing with this scalable process.
Advanced 6-step preparation method for CDK4/6 inhibitor SHR6390. Delivers high purity, mild conditions, and cost reduction in API manufacturing for global supply chains.
Patent CN111848490A details a novel DMAP-catalyzed route for Nintedanib Ethanesulfonate, offering superior purity and supply chain stability for global pharmaceutical manufacturers.